Lilly(Eli) & Company
Open
$1,135.95
Prev. Close
$1,136.47
High
$1,137.69
Low
$1,132.83
Market Snapshot
$1.07T
42.3
11.76
$45.04B
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 50,000 full-time employees. The firm manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
Eli Lilly's AJ1-11095 demonstrated significant efficacy in myelofibrosis, while Jaypirca showed a 45% reduction in disease progression for CLL/SLL patients in Phase 3 trials.
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 50,000 full-time employees. The firm manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
Recently from Cashu
Eli Lilly Launches EBGLYSS: A Game-Changer for Atopic Dermatitis Treatment
Eli Lilly & Company (Ticker: LLY) significantly enhances its commitment to improving patient quality of life by launching the new medication EBGLYSS (lebrikizumab-lbkz) for moderate-to-severe atopic d…
Eli Lilly Advances Obesity Treatment with Promising Results for Retatrutide and Foundayo.
Eli Lilly & Company (Ticker: LLY) establishes a significant footprint in obesity treatment with the promising results from its clinical trials for the new weight loss drug, retatrutide. Recently prese…
Eli Lilly's Strategic Expansion of Obesity and Diabetes Treatments Enhances Patient Access and Growth Potential
Eli Lilly and Company (Ticker: LLY) is making significant strides in expanding access to its obesity and diabetes treatments, a crucial move for both patient care and the company’s future growth. Rece…
Supreme Court's Ruling on Eli Lilly's Medicaid Case Highlights Industry Compliance Risks
Eli Lilly and Company (Ticker: LLY) faces a significant financial challenge following the U.S. Supreme Court's decision to reject its appeal in a notable Medicaid whistleblower case. This ruling maint…